Skip to content

Program of Supervised Occlusive Aerobic Training in People With Fibromyalgia.

A 9-week Program of Supervised Occlusive Aerobic Training in People With Fibromyalgia in a Hospital Setting, and Its Impact on Blood/Plasma Variables, Quality of Life and Functional Autonomy.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06001034
Enrollment
37
Registered
2023-08-21
Start date
2022-09-15
Completion date
2023-05-20
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Keywords

occlusive training

Brief summary

Occlusive training in people with fibromyalgia

Detailed description

Intervention study in people with fibromyalgia with the implementation of a lower body occlusive tool in aerobic exercise. The study aims to descriptively test the impact on quality of life and functional autonomy of occlusive training in a controlled and individualized way in two groups: group 1 aerobic exercise with use of occlusive tool and group 2, aerobic exercise without occlusive tool in a period of 9 weeks twice a week.

Interventions

Impact of supervised occlusive training for 2 days per week for 10 weeks on quality of life and functional autonomy in participants with fibromyalgia.

Sponsors

Universidad Pablo de Olavide
CollaboratorOTHER
Hospital Universitario de Valme
CollaboratorOTHER
Andaluz Health Service
CollaboratorOTHER_GOV
José Carlos Rodríguez Bautista
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Group 1: Aerobic exercise plus occlusive tool. Group 2: Aerobic exercise without occlusive tool.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

A patient meets diagnostic criteria for fibromyalgia if the following three conditions are present: (American Rheumatology Association). Wolfe et al., (2010). * o 1) Widespread Pain Index (WPI) ≥ 7 and Symptom Severity Score (SS Score) ≥ 5 or WPI 3-6 and SS ≥ 9. * Symptoms have been present, at a similar level, during the last three months. * The patient has no other pathology that could explain the pain. * Recent negative COVID-19 test.

Exclusion criteria

* Other associated pathologies that may hinder the development of the research. * Mobility limitations. * Injuries that add to those of the disease itself and hinder mobility. * No medical evaluation of the diagnosis of the disease. * Negative results in the inclusion tests. * Cardiac pathologies. * Blood pressure higher than 130-90 mmHg. * No COVID-19 test.

Design outcomes

Primary

MeasureTime frameDescription
Change in Coenzyme Q10 after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).Coenzyme Q10
Change in total antioxidants after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).TAS
Change in disease impact questionnaire WPI after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).WPI; score between (0-19). The higher the score, the greater the impact of the disease.
Change in disease impact questionnaire SSscore after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).SS score; score between (0-3) in the first half. Score between (0-40); between 1-10 (1 point), between 11-24 (2 points), more than 25 (3 points) in the second half. The higher the score, the greater the impact of the disease.
Change in disease impact questionnaire FIQ after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).FIQ; score between (0-100). The higher the score, the greater the impact of the disease
Change in disease impact questionnaire MFI-20 after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).MFI-20; (0-60) no fatigue. (60-70), fatigue, lighter or more severe, depending on the depending on the rating closer to 60 or 70 points. (more than 70 points), severe fatigue.
Change in high density lipoproteins after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).HDL
Change in low density lipoproteins after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).LDL
Change in total cholesterol lipoproteins after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).CHOL
Change in triglycerides after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).TG
Changes in urea after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).Urea
Changes in creatinine after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).Creatinine
Change in gamma-glutamyl transferase after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).GGT
Change in glutamic-pyruvic transaminase after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).GPT
Change in glutamic oxaloacetic acid transaminase after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).GOT
Change in alkaline phosphatase after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).ALP
Change in funcional test after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period)6-minute walking test
Change in malondialdehyde after a 9-week intervention period.Pre (before the start of the 9-week intervention period). Post (immediately after the 9-week intervention period).MDA (malondialdehyde)
Change in distance traveled after a 9-week intervention period.From week 1 to week 9 of the intervention period.Pedometer registration. Immediately after each session from week 1 to 9 of the intervention period. With a total of 18 recordings over the 9 weeks of the intervention period.
Change in visual pain scale VAS over a 9-week intervention period.From week 1 to week 9 of the intervention period.Visual pain scale (1-10). 1 being lighter and 10 being more severe. Visual pain scale recording. Before and immediately after each session from week 1 to week 9 of the intervention period. With a total of 36 recordings during the 9 weeks of the intervention period.
Change in perceived exertion scale BORG over a 9-week intervention period.From week 1 to week 9 of the intervention period.Perceived exertion scale. (1-10). 1 being lighter and 10 being more severe. Perceived exertion scale recording. Before and immediately after each session from week 1 to week 9 of the intervention period. With a total of 36 recordings during the 9 weeks of the intervention period.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026